366,661 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Bought by Norges Bank

Norges Bank bought a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) during the 4th quarter, Holdings Channel.com reports. The fund bought 366,661 shares of the company’s stock, valued at approximately $22,861,000.

A number of other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of TransMedics Group by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company’s stock worth $226,700,000 after buying an additional 40,860 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of TransMedics Group by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 763,790 shares of the company’s stock valued at $119,938,000 after purchasing an additional 10,106 shares during the last quarter. Emerald Advisers LLC boosted its position in shares of TransMedics Group by 146.3% in the 4th quarter. Emerald Advisers LLC now owns 371,711 shares of the company’s stock worth $23,176,000 after purchasing an additional 220,804 shares in the last quarter. Vaughan Nelson Investment Management L.P. grew its stake in TransMedics Group by 9.9% during the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company’s stock worth $22,547,000 after buying an additional 32,605 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in TransMedics Group by 9.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 297,433 shares of the company’s stock valued at $18,545,000 after buying an additional 25,739 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

TMDX has been the topic of a number of research analyst reports. JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Robert W. Baird decreased their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Canaccord Genuity Group reissued a “buy” rating and set a $104.00 price objective on shares of TransMedics Group in a report on Tuesday, March 11th. Piper Sandler cut their target price on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research report on Wednesday, March 26th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $67.67 on Monday. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.37. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The stock has a market cap of $2.28 billion, a PE ratio of 71.99 and a beta of 2.14. The business has a 50-day simple moving average of $70.07 and a 200-day simple moving average of $84.75.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.